Compare Johnson & Johnson (JNJ) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs MPLX LP — how do they compare? Johnson & Johnson trades at $249.2 (market cap $598.96B), while MPLX LP trades at $56.69 (market cap $57.97B). The key difference: Johnson & Johnson is far larger — about 10.3× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.54%). Which is the better fit depends on your goals.
| JNJ | MPLX | |
|---|---|---|
Market Cap | $598.96B | $57.97B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $59.17 |
52-Week Low | $164.36 | $47.80 |
Enterprise Value | $631.90B | $82.60B |
Dividend Yield | 2.15% | 7.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
MPLX trades at $57.13, up 0.12% today, with a bullish technical signal from moving averages and a consensus analyst price target of $60.00. The company reported strong profitability with a 41.24% net income margin in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights its resilient midstream model and attractive dividend yield.
The outlook for MPLX is positive, supported by stable cash flows, a high dividend yield, and analyst optimism. Key risks include exposure to energy market volatility and a recent earnings miss. The stock offers value with a P/E of 12.35 and strong institutional buy ratings, but investors should monitor execution on growth projects and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
